{
    "id": 20212,
    "cites": 18,
    "cited_by": 14,
    "reference": [
        "Angell, M., 2010. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Bad Pharma, Bad Medicine,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Boston Review, accessed at: http://bostonreview.net/angell-big-pharma-bad-medicine Angell, M., 2012, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Econ Talk: Angell on Big Pharma\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, part of the Library of Economics and Liberty Accessed at http://www.econtalk.org/archives/2012/11/angell_on_big_p.html Bast, J. 2004, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The Pros and Cons of Importing Drugs from Canada\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Press Release by the Heartland Institute, 4/19/2014.",
        "Blume-Kohout, M. E. and N. Sood (2013). \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Market Size and Innovation: Effects of Medicare Part D on Pharmaceutical Research and Development,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Public Economics 97: 327\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c336.",
        "Bowman, Jennifer, Amy Rousseau, David Silk, and Catherine Harrison. 2006. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Access to Cancer Drugs in Medicare Part D: Formulary Placement and Beneficiarcy Cost Sharing in 2006,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Health Affairs, 25(5):1240-48 Cerda, R. A. (2007). \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Endogenous Innovations in the Pharmaceutical Industry,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Evolutionary Economics 17 (4): 473\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c515.",
        "Dubois, Pierre, Olivier de Mouzon, Fiona Scott-Morton, and Paul Seabright. 2014. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Market Size and Pharmaceutical Innovation,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d working paper, March 2014.",
        "Ernst and Young (2012). Beyond Borders: Global Biotechnology Report 2012.",
        "Hirsch, B. R. and G. H. Lyman (2011). \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Biosimilars: Are They Ready for Primetime in the United States?.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of the National Comprehensive Cancer Network 9(8): 934\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c943.",
        "Food and Drug Administration. 2013. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Fast Track, Breakthrough Therapy, Accelerated Approval and Priority Review Expediting Availability of New Drugs for Patients with Serious Conditions,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Accessed online on 4/18/2014 at: http://www.fda.gov/forconsumers/byaudience/forpatientadvocates/speedingaccesstoimporta ntnewtherapies/ucm128291.htm.",
        "Gounder, Celine. 2013. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093A Better Treatment for Hepatitis C,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d The New Yorker, Dec 9 2013.",
        "Grabowski, H. (2008). \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Follow-on Biologics: Data Exclusivity and the Balance Between Innovation and Competition,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Nature Reviews Drug Discovery 7(6): 479\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c488.",
        "Grabowski, H., I. Cockburn, and G. Long (2006). \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The Market for Follow-On Biologics: How Will it Evolve?,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Health Affairs 25 (5): 1291\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c1301.",
        "Hall, S. 2013, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The Rising Costs of Cancer Drugs\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d New York Magazine Published online 10/20/2103.",
        "Accessed online 4/18/2014 at http://nymag.com/news/features/cancer-drugs-2013-10/ Ketcham, J. D. and K. Simon (2008). \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Medicare Part D\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0084\u00a2s effects on Elderly drug costs and utilization\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d American Journal of Managed Care, 14(11): 14-22.",
        "Parker, Ian. 2013. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The Big Sleep,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d The New Yorker, Dec 9 2013.",
        "Rockoff, Jonathan. 2014b. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Sales Soar for Pricey Hepatitis Drug Sovaldi,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Wall Street Journal, March 31, 2014.",
        "Rome, E., 2013, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Big Pharma Pockets $711 Billion in Profits by Robbing Seniors, Taxpayers\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Huffington Post 4/8/2013 Schellekens, Huub. 2004. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093How Similar Do \u00c3\u00a2\u00e2\u0082\u00ac\u00cb\u009cBiosimilars\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0084\u00a2 Need to Be,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Nature Biotechnology, 22(11): 1357-1359.",
        "Spector, R. 2005, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Me too Drugs: Sometimes They\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0084\u00a2re the Same Old Same Old\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Stanford Medicine Magazine Summer 2005. Accessed at http://stanmed.stanford.edu/2005summer/drugsmetoo. html Stern, S., 2004, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Do Scientists Pay to be Scientists?\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Management Science 50(6): 835-53.",
        "Trusheim, Mark R., Murray L. Aitken and Ernst R. Berndt. 2010. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Characterizing Markets for Biopharmaceutical Innovations: Do Biologics Differ from Molecules?,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Forum for Health Economics & Policy 13(1): 1-45.",
        "Ward, M. and D. Dranove, 1997, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The Vertical Chain of Research and Development in the Pharmaceutical Industry\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Economic Inquiry 33(1): 70-87 Yin W. 2008. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Market Incentives and Pharmaceutical Innovation,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Health Economics, 27(4): 1060-77."
    ]
}